Welcome to our dedicated page for Zynex SEC filings (Ticker: ZYXI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to spot FDA risk disclosures or recurring supply revenue inside Zynex’s 200-page reports? Medical-device filings can bury the details that move the stock—whether it’s reimbursement trends, electrode reorder margins, or how new cardiac monitors could reshape growth.
Our platform solves this by linking each disclosure to the exact SEC form you need. The moment a Zynex quarterly earnings report 10-Q filing or Zynex 8-K material events explained hits EDGAR, AI generates a concise summary, flags segment revenue shifts, and highlights anything the market may miss. Real-time alerts surface Zynex Form 4 insider transactions real-time, so you never wait to learn when executives buy or sell.
Here’s what you can explore today:
- Annual perspective: A Zynex annual report 10-K simplified breakdown of FDA pathways, supply-chain dependencies, and reimbursement sensitivity.
- Quarter-to-quarter pulse: Instant AI commentary on margins, unit volume, and cash flow inside each 10-Q.
- Governance clarity: The Zynex proxy statement executive compensation decoded—see how pay aligns with R&D milestones.
- Insider visibility: Track every Zynex executive stock transactions Form 4 alongside trend analytics.
Need quick answers? Ask, “Zynex SEC filings explained simply,” “understanding Zynex SEC documents with AI,” or dive into our Zynex earnings report filing analysis to compare segment growth. Whether you’re researching Zynex insider trading Form 4 transactions or validating forecasts, Stock Titan delivers complete coverage—AI-powered summaries, expert annotations, and real-time updates across every filing type.
Vikram Singh Bajaj filed an SEC Form 3 reporting his initial statement of beneficial ownership for Zynex Inc (ZYXI). The reported event date is 08/18/2025. Mr. Bajaj is identified as an officer with the title Chief Financial Officer. The form states no securities are beneficially owned by the reporting person at the time of filing. The form was signed on 09/03/2025.
Steven Lewis Dyson is reported as both Chief Executive Officer and a director of Zynex Inc (ZYXI) on an initial Form 3. The filing discloses that no securities are beneficially owned by the reporting person and that the Form was filed by a single reporting person. The form shows no non‑derivative or derivative holdings and includes the reporting person’s address.
John T. Bibb, listed as both a Director and the company's Chief Legal Officer, filed an Initial Statement of Beneficial Ownership (Form 3) for Zynex Inc (ZYXI) reporting the event date 08/18/2025. The filing explicitly states that no securities are beneficially owned by the reporting person. The form is signed and dated 08/28/2025.
Zynex Inc. (ZYXI) – Form 4 filing, 29 Jul 2025. Chief Operating Officer Anna Lucsok reported two equity-compensation transactions.
- Restricted Stock Award: On 27 Jul 2025 Lucsok received 7,500 common shares under the 2017 Stock Incentive Plan. The grant vests in equal annual tranches over four years and was issued at $0 cost.
- Tax-Withholding Share Surrender: On 28 Jul 2025 the issuer withheld 3,793 shares (Code F) at an implied value of $2.56 per share to cover payroll taxes related to previously vested RSAs. This is not an open-market sale.
After the transactions, Lucsok directly holds 64,412 shares, most of which remain unvested. No derivatives were involved and there were no cash sales or purchases. The filing modestly increases insider ownership alignment but has immaterial dilution given Zynex’s overall share count. Investor impact is therefore limited and chiefly informative for governance monitoring.
FAQ
What is the current stock price of Zynex (ZYXI)?
What is the market cap of Zynex (ZYXI)?
